# An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis

> **NCT03758716** · PHASE2 · COMPLETED · sponsor: **Fountain Biopharma Inc.** · enrollment: 12 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** FB825, FB825-15D11, Anti-CemX

## Key facts

- **NCT ID:** NCT03758716
- **Lead sponsor:** Fountain Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-03
- **Primary completion:** 2019-01-28
- **Final completion:** 2019-09-19
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03758716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03758716, "An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03758716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*